Additional file 1: of FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

Supplementary material for FUNDAMANT: An interventional 72-week phase 1 follow study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease. (DOCX 4564 kb)